Cronos Group
Canadian LP backed by Altria Group. Focused on disruptive IP and product innovation in cannabis.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Cronos Group earns a Neutral rating with a composite score of 60.06, reflecting a company in transition that combines genuine operational momentum with persistent market and visibility headwinds. The fundamentals pillar delivers a robust 78.02, anchored by exceptional 40% year-over-year revenue growth and a gross margin near 40%. Operating margin has reached near-breakeven at negative 1.1%, a marked improvement that positions the company within striking distance of profitability. With a market capitalization exceeding $1 billion and negligible cash burn, Cronos possesses the balance sheet stamina to execute its growth strategy without immediate dilution risk. The regulatory pillar contributes a solid 73.0, underpinned by its Canadian domicile—a jurisdiction scoring 80 on favorable posture—and a clean enforcement record.
The Neutral designation reflects material drag from the market pillar, which registers just 40.0 due to the absence of actionable quote data, and the editorial pillar at 30.0, signaling minimal newsroom or analyst coverage over recent months. This visibility gap constrains investor sentiment despite operational progress. Cronos stands at a crossroads: the revenue trajectory and margin discipline suggest a company finally monetizing its infrastructure, yet the lack of market pricing transparency and media attention limits capital market engagement.
The critical signal to monitor is whether Cronos can restore continuous trading liquidity and attract coverage, transforming operational strength into market recognition that narrows the gap between fundamental performance and investor awareness.
- Headquarters
- 4491 CONCESSION RD 12, STAYNER, A6, L0M 1S0
- Phone
- (416) 504-0004
- SEC CIK
- 1656472
- Website
- Company website
- Market cap
- $1.03B
- Enterprise value
- $200.7M
- Price to book
- 0.96
- Price to sales
- 6.44
- EV / EBITDA
- 1.90
- Revenue (TTM)
- $159.5M
- Gross profit (TTM)
- $63.2M
- EBITDA
- $-2K
- Operating margin
- -1.1%
- Profit margin
- -1.1%
- Rev growth YoY
- 40.1%
- Return on equity
- 0.4%
- Return on assets
- -0.8%
- EPS est. current year
- $0.13
- Wall St. target price
- $2.51
- Shares outstanding
- 373.7M
- Insider ownership
- 48.5%
- Institutional ownership
- 15.6%
- Beta
- 1.24
- Full-time employees
- 610
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEDAR+
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Cronos Group (CRON)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Cronos Group (CRON), a cannabis-sector equity listed on NASDAQ in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Analyst average price target $3.4.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Profitable detected. (3 bullish signals, 1 bearish signal.)
Canadian LP backed by Altria Group. Focused on disruptive IP and product innovation in cannabis.
Latest price: $2.75 (-0.18%) on NASDAQ.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CRON are maintained by Cannabis Investor News and refreshed throughout the trading day.